JP2010514694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514694A5 JP2010514694A5 JP2009543229A JP2009543229A JP2010514694A5 JP 2010514694 A5 JP2010514694 A5 JP 2010514694A5 JP 2009543229 A JP2009543229 A JP 2009543229A JP 2009543229 A JP2009543229 A JP 2009543229A JP 2010514694 A5 JP2010514694 A5 JP 2010514694A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- fragment
- composition according
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 40
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 16
- 239000013543 active substance Substances 0.000 claims 5
- 238000011374 additional therapy Methods 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 230000029663 wound healing Effects 0.000 claims 3
- 229940123208 Biguanide Drugs 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 150000004283 biguanides Chemical class 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 claims 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical group N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 claims 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 1
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims 1
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims 1
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 102000007156 Resistin Human genes 0.000 claims 1
- 108010047909 Resistin Proteins 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 101150026634 SAA3 gene Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 229940029980 drug used in diabetes Drugs 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87104606P | 2006-12-20 | 2006-12-20 | |
| US60/871,046 | 2006-12-20 | ||
| US90838907P | 2007-03-27 | 2007-03-27 | |
| US60/908,389 | 2007-03-27 | ||
| US91103307P | 2007-04-10 | 2007-04-10 | |
| US60/911,033 | 2007-04-10 | ||
| PCT/US2007/088411 WO2008077145A2 (en) | 2006-12-20 | 2007-12-20 | Treatment of il-1-beta related diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014224090A Division JP5856667B2 (ja) | 2006-12-20 | 2014-11-04 | ＩＬ−１β関連疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514694A JP2010514694A (ja) | 2010-05-06 |
| JP2010514694A5 true JP2010514694A5 (cg-RX-API-DMAC7.html) | 2013-11-07 |
| JP5645409B2 JP5645409B2 (ja) | 2014-12-24 |
Family
ID=39537083
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543229A Expired - Fee Related JP5645409B2 (ja) | 2006-12-20 | 2007-12-20 | ＩＬ−１β関連疾患の治療方法 |
| JP2014224090A Expired - Fee Related JP5856667B2 (ja) | 2006-12-20 | 2014-11-04 | ＩＬ−１β関連疾患の治療方法 |
| JP2015241665A Pending JP2016047844A (ja) | 2006-12-20 | 2015-12-11 | ＩＬ−１β関連疾患の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014224090A Expired - Fee Related JP5856667B2 (ja) | 2006-12-20 | 2014-11-04 | ＩＬ−１β関連疾患の治療方法 |
| JP2015241665A Pending JP2016047844A (ja) | 2006-12-20 | 2015-12-11 | ＩＬ−１β関連疾患の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7695718B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3124045A3 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5645409B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103405768A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007333635B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2673592C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009006709A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2554747C9 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008077145A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5645409B2 (ja) | 2006-12-20 | 2014-12-24 | ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー | ＩＬ−１β関連疾患の治療方法 |
| KR102606597B1 (ko) | 2007-05-29 | 2023-11-29 | 노파르티스 아게 | 항-ｉｌ-1-베타 치료법에 대한 신규 적응증 |
| GB0716778D0 (en) * | 2007-08-29 | 2007-10-10 | Bioeos Ltd | Use |
| CA2710252C (en) * | 2007-12-20 | 2017-03-28 | Xoma Technology Ltd. | Methods for the treatment of gout |
| CA2727171A1 (en) * | 2008-06-06 | 2009-12-10 | Xoma Technology Ltd. | Methods for the treatment of rheumatoid arthritis |
| EP2143735A1 (en) * | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| CA2735940A1 (en) * | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | Methods for treating or preventing il-1.beta. related diseases |
| US9393304B2 (en) * | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| EP2382467A1 (en) * | 2008-12-30 | 2011-11-02 | IKFE GmbH | Biomarkers for adipose tissue activity |
| US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| US20130122008A1 (en) * | 2009-05-06 | 2013-05-16 | Novartis Ag | Anti-IL 1- ß Antibody Combination Therapy |
| CN107243077A (zh) * | 2009-05-29 | 2017-10-13 | 爱克索马美国有限责任公司 | IL‑1β抗体及其结合片段的心血管相关用途 |
| US9884117B2 (en) * | 2009-09-03 | 2018-02-06 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| CN102883748A (zh) * | 2010-05-07 | 2013-01-16 | 爱克索马技术有限公司 | 治疗IL-1β相关状况的方法 |
| CN101822660B (zh) * | 2010-05-13 | 2013-07-10 | 中国人民解放军肾脏病研究所 | 大黄酸类化合物或其盐在制备预防和治疗胰岛β细胞功能衰退药物中的应用 |
| WO2011159717A1 (en) | 2010-06-14 | 2011-12-22 | Baylor Research Institute | Inhibition of pro-inflammatory cytokine induced response |
| CN103596591B (zh) | 2011-02-08 | 2016-08-24 | Abbvie公司 | 骨关节炎和疼痛的治疗 |
| TWI461192B (zh) * | 2011-07-20 | 2014-11-21 | Twi Biotechnology Inc | 降低血脂異常病患之糖化血色素的醫藥組成物 |
| CA2891556A1 (en) * | 2012-11-16 | 2014-05-22 | Novartis Ag | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
| WO2016174082A1 (en) * | 2015-04-28 | 2016-11-03 | Swedish Orphan Biovitrum Ab (Publ) | Compositions comprising anakinra |
| CN106810603B (zh) * | 2015-11-30 | 2020-11-17 | 中国科学院过程工程研究所 | 一种多肽及其应用 |
| JP6959913B2 (ja) * | 2016-05-13 | 2021-11-05 | 国立大学法人 東京大学 | 肝分泌型代謝制御因子阻害作用による肥満関連疾患治療剤 |
| CA3137752A1 (en) * | 2019-05-02 | 2020-11-05 | Thiolab, Llc, | Inhibition of il-1 and il-6 inflammation |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3887699A (en) | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| DE3413608A1 (de) | 1984-04-11 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung |
| US4762914A (en) | 1984-05-18 | 1988-08-09 | Auron Philip E | Truncated protein of interleukin-1 |
| US5077219A (en) | 1984-05-18 | 1991-12-31 | New England Medical Center Hospitals | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
| EP0569687B1 (en) | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
| EP0161901B1 (en) | 1984-05-18 | 1993-12-01 | New England Medical Center Hospitals, Inc. | Human il-1 cDNA sequences encoding biologically-active human il-1 proteins |
| US5484887A (en) | 1984-06-19 | 1996-01-16 | Immunex Corporation | Homogeneous interleukin 1 |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5122459A (en) | 1984-12-31 | 1992-06-16 | Immunex Corporation | Gene encoding biologically active human interleukin 1 |
| US4772685A (en) | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
| US5474899A (en) | 1987-05-13 | 1995-12-12 | Cistron Biotechnology, Inc. | Selective immunoassay for IL-1 β |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68925935T2 (de) | 1988-10-01 | 1996-08-14 | Otsuka Pharma Co Ltd | Antikörper gegen Interleukin-1-beta |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| ES2113856T3 (es) | 1989-02-27 | 1998-05-16 | New England Medical Center Inc | Inhibidores de actividad biologica de il-1. |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| KR0185192B1 (ko) | 1989-10-05 | 1999-04-01 | 제임스 더블유. 데이비 | 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리 |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0546091B1 (en) | 1990-08-29 | 2007-01-24 | Pharming Intellectual Property BV | Homologous recombination in mammalian cells |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| DK1279731T3 (da) | 1991-03-01 | 2007-09-24 | Dyax Corp | Fremgangsmåde til udvikling af bindende miniproteiner |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| IT1247472B (it) | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| JP3571337B2 (ja) | 1992-02-11 | 2004-09-29 | セル ジェネシス，インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| DE69329295T2 (de) | 1992-12-02 | 2001-03-15 | Alkermes Controlled Therapeutics, Inc. | Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung |
| CN1094730A (zh) * | 1993-05-03 | 1994-11-09 | 山道士有限公司 | 肽类化合物 |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| US5959085A (en) | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| US6054287A (en) | 1994-05-27 | 2000-04-25 | Methodist Hospital Of Indiana, Inc. | Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species |
| KR100356550B1 (ko) | 1994-09-09 | 2002-12-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 펩티드의금속염을함유한서방성제제 |
| AU695207B2 (en) | 1995-03-28 | 1998-08-06 | Fidia Farmaceutici S.P.A. | Nanospheres comprising a biocompatible polysaccharide |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| HUP9900870A3 (en) | 1995-06-07 | 2001-04-28 | Alkermes Inc | Composition for sustained release of human growth hormone |
| US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US20030044772A1 (en) | 1997-08-04 | 2003-03-06 | Applied Molecular Evolution [Formerly Ixsys] | Methods for identifying ligand specific binding molecules |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| AU2001259758A1 (en) | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| NZ523080A (en) * | 2000-06-29 | 2004-11-26 | Abbott Lab | Antibodies specific for interleukin-1 alpha and interleukin-2 beta and methods of making and using |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| US20030166069A1 (en) | 2000-11-28 | 2003-09-04 | Amgen, Inc. | Interleukin-1 receptor antagonist-like molecules and uses thereof |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US6727234B2 (en) | 2001-04-03 | 2004-04-27 | University Of Iowa Research Foundation | Isoprenoid analog compounds and methods of making and use thereof |
| EP1423432A4 (en) | 2001-07-26 | 2006-01-11 | Lilly Co Eli | ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA) |
| WO2003025020A1 (en) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Method of constructing camel antibody library |
| CA2675409A1 (en) | 2001-10-19 | 2003-05-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| AU2003208946A1 (en) | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| CN1326879C (zh) | 2002-03-29 | 2007-07-18 | 先灵公司 | 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物 |
| US7572770B2 (en) | 2002-06-27 | 2009-08-11 | University Of Zurich | Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| AU2003246085A1 (en) | 2002-06-28 | 2004-01-19 | Takeda Chemical Industries, Ltd. | Diagnostics/preventives/remedies for respiratory diseases |
| CN100519643C (zh) | 2002-07-19 | 2009-07-29 | 奥默罗斯公司 | 可生物降解的三嵌段共聚物,它们的合成方法和从它制得的水凝胶和生物材料 |
| NZ538569A (en) | 2002-09-06 | 2009-02-28 | Amgen Inc | Therapeutic human anti-IL-1R1 monoclonal antibody |
| US7384635B2 (en) | 2002-11-01 | 2008-06-10 | Alk-Abello A/S | Protein variants of naturally occurring allergens |
| CA2509136C (en) | 2003-01-24 | 2013-10-29 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US20040266993A1 (en) | 2003-06-30 | 2004-12-30 | Evans Glen A. | Non-immunoglobulin binding polypeptides |
| US20050159590A1 (en) | 2003-08-25 | 2005-07-21 | Galit Rotman | Variants of interleukin-1 receptor antagonist: compositions and uses thereof |
| US20050152850A1 (en) | 2004-01-09 | 2005-07-14 | Engebretson Steven P. | Methods and compositions for facilitating metabolic control |
| US7732478B2 (en) | 2004-01-09 | 2010-06-08 | The Trustees Of Columbia University In The City Of New York | Methods for facilitating metabolic control |
| WO2005084696A1 (en) | 2004-03-08 | 2005-09-15 | Universita'degli Studi Di Milano | Methods and agents for controlling intestinal inflammation and mucosal immunity using agents interacting with tir8/sigirr |
| EP1576952A1 (en) | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel microspheres with improved release profile |
| US20060094714A1 (en) | 2004-03-26 | 2006-05-04 | Bayer Pharmaceuticals Corporation | Compounds and their use to treat diabetes and related disorders |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| ES2335232T3 (es) * | 2005-06-21 | 2010-03-23 | Xoma Technology Ltd. | Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta. |
| WO2007042524A2 (en) | 2005-10-14 | 2007-04-19 | Novo Nordisk A/S | Treating diabetes using inhibitors of il-1 |
| AU2007238677B2 (en) | 2006-04-14 | 2011-03-10 | Novartis Ag | Use of IL-I antibodies for treating ophthalmic disorders |
| JP5645409B2 (ja) | 2006-12-20 | 2014-12-24 | ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー | ＩＬ−１β関連疾患の治療方法 |
-
2007
- 2007-12-20 JP JP2009543229A patent/JP5645409B2/ja not_active Expired - Fee Related
- 2007-12-20 RU RU2009127066/15A patent/RU2554747C9/ru active
- 2007-12-20 CN CN2013103563757A patent/CN103405768A/zh active Pending
- 2007-12-20 EP EP16158335.6A patent/EP3124045A3/en not_active Withdrawn
- 2007-12-20 US US11/961,764 patent/US7695718B2/en active Active
- 2007-12-20 AU AU2007333635A patent/AU2007333635B2/en active Active
- 2007-12-20 EP EP07869675A patent/EP2094306A2/en not_active Withdrawn
- 2007-12-20 MX MX2009006709A patent/MX2009006709A/es active IP Right Grant
- 2007-12-20 CA CA2673592A patent/CA2673592C/en active Active
- 2007-12-20 WO PCT/US2007/088411 patent/WO2008077145A2/en not_active Ceased
-
2010
- 2010-02-23 US US12/710,842 patent/US8101166B2/en active Active
- 2010-04-09 US US12/757,885 patent/US8586036B2/en not_active Expired - Fee Related
-
2013
- 2013-09-30 US US14/042,205 patent/US9163082B2/en active Active
-
2014
- 2014-11-04 JP JP2014224090A patent/JP5856667B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-21 RU RU2015114923A patent/RU2015114923A/ru not_active Application Discontinuation
- 2015-12-11 JP JP2015241665A patent/JP2016047844A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514694A5 (cg-RX-API-DMAC7.html) | ||
| RU2009127066A (ru) | СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ | |
| Cavelti-Weder et al. | Development of an interleukin-1β vaccine in patients with type 2 diabetes | |
| JP6143416B2 (ja) | 抗体製剤 | |
| WO2002096461A1 (en) | Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients | |
| JP2011507891A5 (cg-RX-API-DMAC7.html) | ||
| JP2006523682A5 (cg-RX-API-DMAC7.html) | ||
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| JPH09510434A (ja) | 重症の急性膵炎を改善するインターロイキン−１レセプター拮抗薬 | |
| AU2019209491B2 (en) | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| US20220257755A1 (en) | Combination therapy for the treatment of autoimmune diseases | |
| Mittermayer et al. | Addressing unmet medical needs in type 1 diabetes: a review of drugs under development | |
| JP2013518863A (ja) | 代謝障害の治療 | |
| AU756167B2 (en) | Application of TNF antagonists as medicaments for treating septic diseases | |
| TW202417505A (zh) | Actrii抗體固定單位劑量治療 | |
| US20220241381A1 (en) | Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone | |
| CN101039679A (zh) | 替加环素和地高辛的共投与 | |
| EP0761688A2 (en) | Production, and therapeutic combinations, of antibodies | |
| JP2023510523A (ja) | 慢性腎疾患及び２型糖尿病における糖尿病性腎疾患の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト | |
| EP3389704B1 (en) | Vaccination against diabetes, obesity and complications thereof | |
| KR20220110506A (ko) | 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제를 사용하는 조합 치료법 | |
| EA048509B1 (ru) | Способы лечения диабета, гепатита и/или воспалительного заболевания печени | |
| MXPA00003355A (en) | Application of tnf antagonists as medicaments for treating septic diseases | |
| CZ20001407A3 (cs) | Použití TNF antagonistů pro výrobu drog k léčení septických poruch |